Article
Prediction of binding of FDA approved drug Ledipasvir to SARS-CoV2 mutants: an in silico study
2021-09-07
Abstract excerpt
The surge of variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) is a global concern to public health as the mutations in the genome may alter the virulence of the virus, which poses a challenge to manage the disease. The virus depends on RNA dependent RNA polymerases [RdRp(s)] and its associated non-structural proteins for replication. Therefore, RdRp is a target of antiviral drugs. Several mu...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- f4d6a945-8f5e-5c02-a8e3-1ac9c746b3e2
- DOI
- 10.21203/rs.3.rs-882289/v1
